全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Impact of IL12B Gene rs 3212227 Polymorphism on Fibrosis, Liver Inflammation, and Response to Treatment in Genotype 4 Egyptian Hepatitis C Patients

DOI: 10.1155/2013/627589

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction. Hepatitis C virus (HCV) infection affects almost 3% of the world's population with the highest prevalence in Egypt (15%). The standard therapy; pegylated interferon (PEG-IFN) and ribavirin, is effective in only 60% of Egyptian patients; moreover it is costly, prolonged, and has severe side effects, so prediction of response is essential to reduce burden of unfavorable treatment. Several viral and host factors have been proved to affect response to the treatment PEG-IFN and ribavirin; the strongest of them is polymorphisms near IL28B; nonetheless, nonresponse in patients with favorable IL28B is still unexplained, which implies the importance of studying other immunological factors that may correlate with response. Interleukin 12 (IL-12) is one of the most important proinflammatory cytokine presented with the initiation of immune response, determining Th1 and Th2 differentiation. A functional single nucleotide polymorphism (A/C) at the 3′ untranslated region (3′UTR) at position 1188 (NCBI SNP database no 3212227) was reported to be associated with responding more efficiently to antiviral combination therapy in HCV genotype 1 infected patients. The present study aims to evaluate association between this polymorphism with fibrosis stages, necroinflammation activity, response to the combined therapy, and gender in Egyptian HCV genotype 4. Material and Methods. A total of 133 Egyptian chronic HCV (CHCV) patients were treated with IFN/RBV and were followed up. IL12B 1188 A/C genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism (PRC-RFLP) analysis. Results. A nonsignificant trend for higher sustained virological response (SVR) was observed in patients homozygote for IL12B 1188 A/C SNP CC genotype (69% SVR versus 30.8% NR) only but not in AC and AA genotypes. No association was detected between IL12B 1188 A/C polymorphism and less severe fibrosis or less liver activity. By stratification of response according to gender genotype, a significant difference in response between males and females was seen among AA genotype carriers only due to high number of non responder females. Conclusion. IL12B CC genotype appears to have some influence on SVR achievement but not on severe fibrosis and severe necroinflamation activity. Females carrying A/A genotype of IL12B 1188 A/C SNP achieve less SVR than those carrying AC and CC genotypes. 1. Introduction Hepatitis C “The Silent Killer” is a liver disease which means inflammation of the liver caused by the hepatitis C virus (HCV). It is suspected that there are, at

References

[1]  S. Rehman, U. A. Ashfaq, S. Riaz, T. Javed, and S. Riazuddin, “Antiviral activity of Acacia nilotica against Hepatitis C Virus in liver infected cells,” Virology Journal, vol. 8, article 220, 2011.
[2]  M. J. Alter, “Epidemiology of hepatitis C virus infection,” World Journal of Gastroenterology, vol. 13, no. 17, pp. 2436–2441, 2007.
[3]  P. Ferenci, S. Ferenci, C. Datz, I. Rezman, W. Oberaigner, and R. Strauss, “Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s,” Journal of Hepatology, vol. 47, no. 1, pp. 31–36, 2007.
[4]  J.-C. Duclos-Vallee and M. Sebagh, “Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation,” Liver Transplantation, vol. 15, supplement 2, pp. S25–S34, 2009.
[5]  G. Borroni, M. Andreoletti, M. A. Casiraghi et al., “Effectiveness of pegylated interferon/ribavirin combination in “real world” patients with chronic hepatitis C virus infection,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 9, pp. 790–797, 2008.
[6]  M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001.
[7]  L. Wan, Y.-J. Kung, Y.-J. Lin et al., “Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with interferon-α,” Biochemical and Biophysical Research Communications, vol. 379, no. 4, pp. 855–860, 2009.
[8]  M. Del Vecchio, E. Bajetta, S. Canova et al., “Interleukin-12: biological properties and clinical application,” Clinical Cancer Research, vol. 13, no. 16, pp. 4677–4685, 2007.
[9]  G. Trinchieri, S. Pflanz, and R. A. Kastelein, “The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses,” Immunity, vol. 19, no. 5, pp. 641–644, 2003.
[10]  W. T. Watford, M. Moriguchi, A. Morinobu, and J. J. O'Shea, “The biology of IL-12: coordinating innate and adaptive immune responses,” Cytokine and Growth Factor Reviews, vol. 14, no. 5, pp. 361–368, 2003.
[11]  D. Huang, M. R. Cancilla, and G. Morahan, “Complete primary structure, chromosomal localisation, and definition of polymorphisms of the gene encoding the human interleukin-12 p40 subunit,” Genes and Immunity, vol. 1, no. 8, pp. 515–520, 2000.
[12]  D. Seegers, A. Zwiers, W. Strober, A. S. Pe?a, and G. Bouma, “A TaqI polymorphism in the 3′ UTR of the IL-12 p40 gene correlates with increased IL-12 secretion,” Genes and Immunity, vol. 3, no. 7, pp. 419–423, 2002.
[13]  A. Houldsworth, M. Metzner, S. Rossol et al., “Polymorphisms in the IL-12B gene and outcome of HCV infection,” Journal of Interferon and Cytokine Research, vol. 25, no. 5, pp. 271–276, 2005.
[14]  M. A. Hall, E. McGlinn, G. Coakley et al., “Genetic polymorphism of IL-12 p40 gene in immune-mediated disease,” Genes and Immunity, vol. 1, no. 3, pp. 219–224, 2000.
[15]  T. Mueller, A. Mas-Marques, C. Sarrazin et al., “Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection,” Journal of Hepatology, vol. 41, no. 4, pp. 652–658, 2004.
[16]  S. A. Miller, D. D. Dykes, and H. F. Polesky, “A simple salting out procedure for extracting DNA from human nucleated cells,” Nucleic Acids Research, vol. 16, no. 3, p. 1215, 1988.
[17]  D. Sieburth, E. W. Jabs, J. A. Warrington et al., “Assignment of genes encoding a unique cytokine (IL12) composed of two unrelated subunits to chromosomes 3 and 5,” Genomics, vol. 14, no. 1, pp. 59–62, 1992.
[18]  A. L. Van Dyke, M. L. Cote, A. S. Wenzlaff, S. Land, and A. G. Schwartz, “Cytokine SNPs: comparison of allele frequencies by race and implications for future studies,” Cytokine, vol. 46, no. 2, pp. 236–244, 2009.
[19]  Z. Farooqi, M. Afzal, S. Tahir, N. Zaidi, and I. Qadri, “Interleukin-12 P40 (IL-12 B) Taq-1 Polymorphism association in pharmacogenomics of HCV genotype 3a infection from Pakistani population,” in Proceedings of the International Conference on Environmental, Biomedical and Biotechnology, 2011.
[20]  P. V. Suneetha, A. Goyal, S. S. Hissar, and S. K. Sarin, “Studies on TAQ1 polymorphism in the 3′untranslated region of IL-12P40 gene in HCV patients infected predominantly with genotype 3,” Journal of Medical Virology, vol. 78, no. 8, pp. 1055–1060, 2006.
[21]  J. L. Narciso-Schiavon, L. D. L. Schiavon, R. J. Carvalho-Filho et al., “Gender influence on treatment of chronic hepatitis C genotype 1,” Revista da Sociedade Brasileira de Medicina Tropical, vol. 43, no. 3, pp. 217–223, 2010.
[22]  H. Sezaki, F. Suzuki, Y. Kawamura et al., “Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads,” Digestive Diseases and Sciences, vol. 54, no. 6, pp. 1317–1324, 2009.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133